SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-011375
Filing Date
2023-06-23
Accepted
2023-06-23 16:05:11
Documents
12
Period of Report
2023-06-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20230622x8k.htm   iXBRL 8-K 70303
  Complete submission text file 0001558370-23-011375.txt   190579

Data Files

Seq Description Document Type Size
2 EX-101.SCH kala-20230622.xsd EX-101.SCH 3126
3 EX-101.LAB kala-20230622_lab.xml EX-101.LAB 15266
4 EX-101.PRE kala-20230622_pre.xml EX-101.PRE 9658
6 EXTRACTED XBRL INSTANCE DOCUMENT kala-20230622x8k_htm.xml XML 4688
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
Kala Pharmaceuticals, Inc. (Filer) CIK: 0001479419 (see all company filings)

IRS No.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 231037660
SIC: 2834 Pharmaceutical Preparations